胃癌D2切除后高危患者放化疗对比化疗的长期预后分析
这项随机临床试验纳入312例胃癌D2切除术后患者,比较术后放化疗与辅助化疗的3年无病生存(DFS)。高危组(pN≥N2且胃周外淋巴结转移)3年DFS为59.3%,低于低危组的76.8%。
要点
- 高危组(pN≥N2且胃周外淋巴结转移)3年DFS为59.3%,低于低危组的76.8%。
- 高危患者中放化疗组3年DFS为71.0%,优于化疗组的53.0%。
核心结论
- 亚组分析显示高危胃癌患者可从术后放化疗中获益。
关键数值与推荐
- 高危定义为pN分期≥N2且存在胃周外淋巴结转移。
- 放疗方案:45 Gy分25次,每次1.8 Gy,5周内完成,调强放疗,同期S-1化疗。
- 辅助化疗方案:8周期SOX(S-1+奥沙利铂);放疗在4-6周期SOX化疗后给予。
- 主要终点为3年无病生存(DFS)。
临床怎么用
- 对于D2切除术后高危(pN≥N2且胃周外淋巴结转移)胃癌患者,可考虑术后放化疗。
- 放化疗方案为调强放疗45 Gy/25次同期S-1化疗,放疗前接受4-6周期SOX化疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the population of patients who could benefit from adjuvant radiation therapy (RT) and investigated the value of postoperative chemoradiation therapy (CRT) in patients with gastric cancer after D2 resection. METHODS AND MATERIALS: This randomized clinical trial enrolled patients between October 1, 2011, and December 31, 2019. Patients with gastric cancer who underwent D2 gastrectomy were randomized (1:1) to receive postoperative CRT or adjuvant chemotherapy after surgery. The adjuvant chemotherapy group received 8 cycles of SOX (S-1 + oxaliplatin) chemotherapy. RT was given after 4 to 6 cycles of SOX chemotherapy. RT comprised 45 Gy in 25 fractions of 1.8 Gy over 5 weeks by intensity modulated RT concurrently with S-1 chemotherapy. The primary endpoint was 3-year disease-free survival (DFS). RESULTS: A total of 312 patients (median [IQR] age, 58 [50-64] years) were enrolled, including 157 patients randomized to the adjuvant chemotherapy group and 155 patients randomized to the adjuvant CRT group. The 3-year DFS was 66.7% for the control arm and 70.7% for the experimental arm (hazard ratio [HR], 0.82; 95% CI, 0.54-1.25; P = .35). We defined patients with pN stage ≥ N2 and extraperigastric lymph node metastasis as the high-risk group and the remaining patients as the low-risk group. The 3-year DFS rates for the high-risk group and the low-risk group were 59.3% and 76.8%, respectively (HR, 2.11; 95% CI, 1.39-3.22; P < .01). For high-risk patients, the 3-year DFS rates in the adjuvant chemotherapy and adjuvant CRT groups were 53.0% and 71.0%, respectively (HR, 0.53; 95% CI, 0.29-0.97; P < .05). More grade 3 and 4 acute toxic effects were observed in the adjuvant chemotherapy group than in the CRT group (41 patients [26.1%] vs 28 patients [18.5%]; P = .11), but the difference was not significant. CONCLUSIONS: Subgroup analysis of this randomized clinical trial revealed that high-risk patients can benefit from adjuvant CRT.
引用
- Qiao XX, Jiang HG, Tang Y, et al. Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 40185210. doi:10.1016/j.ijrobp.2025.03.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。